{"title":"GSK收购巴西利亚公司的Toctino®，加强其皮肤科业务","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1757","DOIUrl":null,"url":null,"abstract":"In exchange for £146 M (US$226 M) upfront, GlaxoSmithKline’s Stiefel Laboratories has acquired exclusive worldwide rights to Basilea Pharmaceutica’s chronic hand eczema drug Toctino® (oral alitretinoin), which is marketed in 14 countries and reported sales of CHF31 M (US$35 M) in 2011. Basilea is also entitled to receive up to an additional £50 M (US$77 M) upon US FDA approval as well as double-digit royalties beginning 3 years after launch. Basilea will use the cash proceeds from the transaction to advance its pipeline of anti-infective and oncology drugs.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"141 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"GSK Strengthens its Dermatology Business with Acquisition of Basilea’s Toctino®\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I6.1757\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In exchange for £146 M (US$226 M) upfront, GlaxoSmithKline’s Stiefel Laboratories has acquired exclusive worldwide rights to Basilea Pharmaceutica’s chronic hand eczema drug Toctino® (oral alitretinoin), which is marketed in 14 countries and reported sales of CHF31 M (US$35 M) in 2011. Basilea is also entitled to receive up to an additional £50 M (US$77 M) upon US FDA approval as well as double-digit royalties beginning 3 years after launch. Basilea will use the cash proceeds from the transaction to advance its pipeline of anti-infective and oncology drugs.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"141 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I6.1757\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I6.1757","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
GSK Strengthens its Dermatology Business with Acquisition of Basilea’s Toctino®
In exchange for £146 M (US$226 M) upfront, GlaxoSmithKline’s Stiefel Laboratories has acquired exclusive worldwide rights to Basilea Pharmaceutica’s chronic hand eczema drug Toctino® (oral alitretinoin), which is marketed in 14 countries and reported sales of CHF31 M (US$35 M) in 2011. Basilea is also entitled to receive up to an additional £50 M (US$77 M) upon US FDA approval as well as double-digit royalties beginning 3 years after launch. Basilea will use the cash proceeds from the transaction to advance its pipeline of anti-infective and oncology drugs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
